U.S. Health Agencies Seek Biomarkers for Better Cancer Therapies
Posted on: Wednesday, 15 February 2006, 09:00 CST
U.S. health agencies seek biomarkers for better cancer therapies
WASHINGTON, Feb. 14 (Xinhua) -- U.S. federal health agencies on Tuesday announced a project to seek biological markers that will show the effect of therapies on cancer patients in order to predict tailored treatments.
Scientists have discovered many potentially useful biomarkers, and some are being used in treating many diseases to determine the use or experiment of certain therapy for a patient, and to speed drug development.
The U.S. Food and Drug Administration (FDA) sometimes based its approval of new cancer drugs on some biomarkers. However, some of the biomarkers in use today need yet to be further understood and don't work well.
The three U.S. federal agencies, the FDA, National Cancer Institute and Medicare, will collaborate to find better biomarkers for cancer, or better ways to measure and use them.
They will begin with non-Hodgkin's lymphoma. A study is intended to see whether a special type of PET scan that measures cellular metabolism can indicate how a patient responds to treatment.
Source: Xinhua News Agency - CEIS
Related Articles
- Nanosensors Measure Cancer Biomarkers In Blood
- Intense bladder cancer therapy not better
- Pancreatic cancer biomarkers list created
- Research and Markets: In 2007, the Estimated Cancer Biomarker Market Accounted for Around 55% of Biomarker Revenues at Over US$3 Billion
- Lixte Announces Filing of New Patent Application for Cancer Biomarker
- Fujirebio Gets Patent for Cancer Biomarker
- Miraculins Announces Positive Final Results in Pivotal Prostate Cancer Biomarker Study
- Integrating Cancer Biomarkers into Clinical Practice is the Goal for Development Companies As Well As Clinicians
- Upstream Biosciences Seeks US Patent for Ovarian Cancer Biomarkers
 |
 |
User Comments (0)
RSS Feeds